Free Trial

ResMed (RMD) Stock Forecast & Price Target

ResMed logo
$270.54 +3.23 (+1.21%)
Closing price 09/26/2025 03:59 PM Eastern
Extended Trading
$273.08 +2.54 (+0.94%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
3
Buy
11

Based on 14 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 3 have given a hold rating, 9 have given a buy rating, and 2 have given a strong buy rating for RMD.

Consensus Price Target

$294.20
8.75% Upside
According to the 14 analysts' twelve-month price targets for ResMed, the average price target is $294.20. The highest price target for RMD is $330.00, while the lowest price target for RMD is $270.00. The average price target represents a forecasted upside of 8.75% from the current price of $270.54.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RMD Analyst Ratings Over Time

TypeCurrent Forecast
9/29/24 to 9/29/25
1 Month Ago
8/30/24 to 8/30/25
3 Months Ago
7/1/24 to 7/1/25
1 Year Ago
9/30/23 to 9/29/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
9 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$294.20$274.83$259.33$212.25
Forecasted Upside8.75% Upside0.02% Upside1.21% Upside-11.19% Downside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ResMed Stock vs. The Competition

TypeResMedMedical CompaniesS&P 500
Consensus Rating Score
2.93
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside8.75% Upside2,562.73% Upside11.53% Upside
News Sentiment Rating
Very Positive News

See Recent RMD News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/18/2025Citigroup
3 of 5 stars
Laura Sutcliffe
Not Rated
Initiated CoverageBuy$330.00+21.36%
9/16/2025UBS Group
4 of 5 stars
Laura Sutcliffe
Not Rated
UpgradeStrong-Buy
9/2/2025CLSA
1 of 5 stars
 UpgradeHoldOutperform
8/1/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeStrong-Buy
8/1/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$294.00 ➝ $300.00+7.31%
8/1/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetHold$240.00 ➝ $270.00-3.42%
8/1/2025Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$270.00 ➝ $290.00+3.73%
8/1/2025KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$274.00 ➝ $298.00+9.49%
8/1/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$248.00 ➝ $270.00-0.79%
5/20/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetOverweight$286.00+16.50%
4/24/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$286.00 ➝ $290.00+22.49%
1/31/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
1/16/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
10/25/2024Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$280.00 ➝ $283.00+18.39%
9/26/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$240.00 ➝ $270.00+11.12%
9/24/2024Baird R W
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/18/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingPeer PerformUnderperform$180.00-28.25%
6/25/2024Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeOutperformMarket Perform
10/5/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower Target$240.00 ➝ $165.00+11.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 08:18 AM ET.


Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 26, 2025. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in ResMed Inc.:

  • The current stock price is around $279, reflecting a strong position in the market.
  • ResMed Inc. reported a quarterly earnings per share (EPS) of $2.55, exceeding analyst expectations, indicating robust financial performance.
  • The company has shown a revenue increase of over 10% compared to the same quarter last year, suggesting growth potential.
  • ResMed Inc. has a healthy net margin of 27.22%, which indicates effective cost management and profitability.
  • The recent increase in the quarterly dividend to $0.60, with a yield of 0.9%, demonstrates a commitment to returning value to shareholders.

ResMed
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in ResMed Inc. for these reasons:

  • Insider selling activity has been noted, with significant shares sold recently, which may raise concerns about the company's future outlook.
  • Company insiders own only 0.71% of the stock, which could indicate a lack of confidence in the company's long-term prospects.
  • The stock has experienced fluctuations, with a recent average price of $275.98 over the last fifty days, suggesting volatility.
  • Despite strong earnings, the overall market conditions for medical devices can be unpredictable, impacting future performance.
  • The dividend payout ratio is at 25.24%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.

RMD Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $294.20, with a high forecast of $330.00 and a low forecast of $270.00.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 3 hold ratings, 9 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RMD shares.

According to analysts, ResMed's stock has a predicted upside of 8.75% based on their 12-month stock forecasts.

Over the previous 90 days, ResMed's stock had 4 upgrades by analysts.

ResMed has been rated by research analysts at Citigroup, CLSA, KeyCorp, Mizuho, Piper Sandler, Royal Bank Of Canada, Stifel Nicolaus, UBS Group, and William Blair in the past 90 days.

Analysts like ResMed more than other "medical" companies. The consensus rating score for ResMed is 2.93 while the average consensus rating score for "medical" companies is 2.78. Learn more on how RMD compares to other companies.


This page (NYSE:RMD) was last updated on 9/29/2025 by MarketBeat.com Staff
From Our Partners